Conclusion
To summarize, the use of nirmatrelvir-ritonavir within 10 days of
symptom onset or a positive RT-PCR result is linked to a reduced
duration of RT-PCR conversion in high-risk patients infected with
SARS-CoV-2. This expands the potential use of nirmatrelvir-ritonavir
beyond its labeled indications.